STADA Specialty and Biosimilars
STADA Specialty and Biosimilars:
Opening doors to more affordable, life-changing treatments
At STADA, Thornton & Ross, we offer expertise and outstanding value in Specialty Pharmaceuticals and we are continuously expanding our portfolio. Our biosimilars and specialty medicines enable improved access to treatment for patients across a broad range of therapy areas.
2006
The introduction of the first biosimilar in clinical use
>30
Biosimilars approved for use in the EU to date as of March 2019
20 to 25%
Savings compared to reference products
NEW ustekinumab biosimilar
UZPRUVO®▼ (ustekinumab)
Uzpruvo is STADA’s ustekinumab biosimilar and offers a cost-effective alternative to the reference product.1,2
Uzpruvo (ustekinumab) is indicated for the treatment of moderate to severe Crohn’s disease in adults, moderate to severe plaque psoriasis in adults, moderate to severe paediatric plaque psoriasis and psoriatic arthritis in adults.1
Uzpruvo is currently not approved for the Ulcerative Colitis indication (since the originator still has exclusivity for this indication).
Kinpeygo® 4mg▼ (modified-release hard capsules budesonide)
Kinpeygo – the first and only disease-modifying treatment approved across Europe and by NICE specifically for use in IgA nephropathy3,4
Kinpeygo is indicated for the treatment of primary immunoglobulin A (IgA) nephropathy (IgAN) in adults at risk of rapid disease progression with urine protein-to-creatinine ratio (UPCR) ≥ 1.5g/gram.5
XIMLUCI®▼ (ranibizumab)
Our first ophthalmology biosimilar, ranibizumab is a biological medicine that is injected into the eye. XIMLUCI is the ranibizumab biosimilar from STADA Thornton and Ross.6
XIMLUCI is indicated for adult patients, treatment of: neovascular (wet) age-related macular degeneration (AMD); visual impairment due to diabetic macular oedema (DME); proliferative diabetic retinopathy (PDR); visual impairment due to macular oedema secondary to retinal vein occlusion (branch RVO or central RVO); visual impairment due to choroidal neovascularisation (CNV).6
Prescribing Information can be found here
MOVYMIA®▼ (teriparatide)
MOVYMIA the teriparatide biosimilar from Thornton & Ross, STADA. MOVYMIA® is indicated for adults for the treatment of osteoporosis in postmenopausal women and in men at increased risk of fracture.7
Prescribing Information can be found here
Let’s stay connected!
Want to be the first to hear about the products, services and educational resources we offer, including invitations to webinars and events?
STADA biosimilars: Making effective medicine accessible
STADA: Caring for people’s health as a trusted partner
STADA is a leading European company, established by physicians and pharmacists. Manufacturing and distributing pharmaceuticals for more than 125 years.
Key Facts:
+125 years
years of heritage
+15 years
of biosimilars experience
~120 countries
selling STADA products
+13,000 employees
around the globe
Biosimilars – a lifeline for people with unmet medical needs:
 |
Demonstrate equivalent biological activity to their corresponding reference drugs |
|
Improve cost-effectiveness |
|
Provide alternatives for decision makers (e.g. prescribers, regulators, payers, policymakers) |
|
Enhance treatment accessibility for patients |
Our biosimilars enable improved access to treatment for patients across a broad range of indications
What is a Biosimilar?
A biosimilar is a biologic that is highly similar to another biologic medicine:8
Large molecule with a complex structure
Produced from living cells
Strictly regulated biomanufacturing and quality control
Biosimilars are approved according to the same strict standards of safety, efficacy and tolerability as other medicines:8
Undergo clinical studies
Manufactured in licensed facilities
Approved using the same regulatory pathway as reference product
Biosimilars have been trusted medicines in Europe for over 15 years, since the first European biosimilar approval in 20068
NHS Biosimilar Adoption Guidance9
NHS England and NHS Improvement supports the appropriate use of biosimilar medicines which will drive greater competition and release cost savings to support the treatment of an increasing number of patients and the uptake of new and innovative medicines.
At least 90% of new patients will be prescribed the best value biological medicine within 3 months of launch of a biosimilar medicine
This guidance is designed to support the NHS to achieve this.
Excerpt from NHS Comissioning framework for biological medicines.9
See full NHS report here
References
- Uzpruvo SmPC. Last accessed: July 2024.
- Cost of Uzpruvo and reference product (Stelara) taken from NHS DM+D. Last accessed: July 2024.
- European public assessment report (EPAR) Kinpeygo. EMA/570757/2022. Last accessed: July 2024
- Overview | Targeted-release budesonide for treating primary IgA nephropathy | Guidance | NICE. Published: 20 December 2023. Last accessed: July 2024
- Kinpeygo SmPC. Available at: https://www.medicines.org.uk/emc/product/15393. Accessed July 2024.
- XIMLUCI (ranibizumab) Summary of Product Characteristics. January 2023. Last accessed: July 2024.
- Movymia 20 micrograms/80 microliters solution for injection Summary of Product Characteristics (SmPC). Last accessed: July 2024.
- Biosimilar Medicinces Group. Biosimilar Medicines Handbook. 3rd edition 2016. Last accessed: July 2024.
- Commissioning framework for biological medicines (including biosimilar medicines). Last accessed: July 2024.
Adverse events should be reported to Thornton and Ross Limited by emailing thorntonross@medinformation.co.uk or by calling 01484 848164. Additionally, reporting forms and information can be found at: https://yellowcard.mhra.gov.uk or search for MHRA Yellow Card in the Google Play or Apple App Store.
UK-MULT-122(3) | July 2024